Merger Update: NCLAT approves Rs 155 acquisition of THIS pharma company - Details

The National Company Law Appellate Tribunal (NCLAT) approved the merger of Casper Pharma with Suven Pharmaceuticals, valued at Rs 155 crore. This merger aims to enhance Suven’s production capabilities and streamline operations. Casper Pharma, acquired by Suven in April 2022, has a production capacity of 120 crore tablets and capsules. The merger is expected to bring efficiency through consolidation, better utilization of resources, reduction in overheads, and economies of scale. The tribunal’s order highlighted that the merger scheme is fair, reasonable, and legally sound. Legal representatives argued that the amalgamation would bring concentrated management focus and integration with uniform management procedures, enabling smooth policy implementation. The merger will optimize costs, tap into new revenue streams, and strengthen Suven’s competitive position in the pharmaceutical industry. The streamlined group structure will help in better capital utilization and pave the way for future growth and innovation in the pharma sector.